In the realm of toxicology, NK1 receptor antagonists are valuable for their potential to alleviate symptoms associated with exposure to toxic agents. Their ability to block substance P makes them effective in reducing chemotherapy-induced nausea and vomiting (CINV), a common issue for cancer patients exposed to toxic chemotherapeutic agents. By controlling these symptoms, NK1 receptor antagonists improve patients' quality of life and adherence to treatment regimens.
